[Chronic granulomatous disease (CGD): in vitro enhancement of bactericidal activity of CGD phagocytes by rifampicin].
In a series of 29 experiments on CGD patients, we have studied the in vitro bactericidal capacity of normal and CGD phagocytes against penicillin, streptomycin and rifampicin sensitive Staphylococcus aureus. The bactericidal activity of phagogyte preparations was tested at different intervals during a 21 hour incubation. The CGD-phagocyte bactericidy peaks after 90 min when penicillin is used; in contrast, a significant enhancement of the bactericidal activity is noted with rifampicin and best noted after 21 hours of incubation. To elucidate the mode of action of this antibiotic, a rifampicin resistant S. aureus was used in a series of experiments; The results  point to a mixt type of action: antimicrobial and metabolic.
D001770:Blood Bactericidal Activity; D006105:Granulomatous Disease, Chronic / Q000188:drug therapy*; D006801:Humans; D010585:Phagocyte Bactericidal Dysfunction / Q000188:drug therapy*; D010586:Phagocytes; D012293:Rifampin / Q000627:therapeutic use*; D013211:Staphylococcus aureus / Q000276:immunology
D012293:Rifampin
Granulomatose septique chronique: modification du pouvior bactéricide des phagocytes par la rifampicine